Full Press Release Details
Cadrenal Therapeutics Announces Appointment
of Robert Lisicki to Board of Directors
PONTE VEDRA, Fla., July
24, 2023 -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company
developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today
announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings
over 25 years of experience in the pharma/biotech sector, including as the Chief Commercial Officer of Arena Pharmaceuticals, where he
provided global visionary leadership for the $6.7 billion growth-stage biopharmaceutical company through their acquisition by Pfizer in
accomplished executive with a proven track record leading rapidly growing clinical-stage public companies, including successes with cardiovascular
therapeutics and strong relationships with life sciences investors. His experience in developing collaborative research agreements with
large pharma across multiple therapeutic areas will be a valuable asset as we look to advance tecarfarin," said Quang Pham, Chairman
and CEO of Cadrenal. "I look forward to leaning on his executive experience and commercial vision as a member of the Cadrenal board."
During his time as Chief
Commercial Officer at Arena Pharmaceuticals, Lisicki had a leadership role in more than $8 billion in M&A activities. He regularly
interacted with FDA, EMA, and PDMA on study and protocol designs.
Prior to Arena, Lisicki
was Vice President, General Manager of Inflammation & Immunology and Cardiovascular at Regeneron Pharmaceuticals, where he was responsible
for both commercial and development stage efforts. From 2014 through 2018, Lisicki was Senior Vice President and Chief Customer Officer
of Daichii-Sanyko, where he managed the successful global product launches in Cardiovascular and successful U.S. development in Pain and
Oncology. From 2005 through 2014, he held key global roles with Amgen. Lisicki earned his BS in Finance and Economics from State University
of New York at Albany.
believe Cadrenal Therapeutics is developing a novel and potentially paradigm-changing therapeutic," said Robert Lisicki. "I
look forward to working with the team to advance the development and value that Tecarfarin may bring to serious and life-threatening diseases."
Lisicki will occupy a
newly created seat on the Cadrenal Board of Directors.
About Cadrenal Therapeutics, Inc.
Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) with orphan drug and Fast
Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease,
or ESKD, and atrial fibrillation. Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most
commonly prescribed Vitamin K antagonist (warfarin) used in the prevention of thrombosis. Tecarfarin has been evaluated in eleven (11)
human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been
well-tolerated in both healthy adult subjects and patients with chronic kidney disease (CKD). For more information, please visit: www.cadrenal.com.
Safe Harbor Statement
statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding
the contributions to be derived from the appointment of Robert Lisicki as a member of the board of directors. The
words "anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project," "should,"
"target," "will," "would" and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, including the ability to derive the anticipated benefits
from Mr. Lisicki's appointment to the Board of Directors and the risk factors described in the Company's Annual Report on
Form 10-K for the year ended December 31, 2022, and the Company's subsequent filings with the SEC, including subsequent periodic
reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release
speak only as of the date hereof and, except as required by federal securities laws, Cadrenal Therapeutics specifically disclaims any
obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Lytham Partners, LLC
Robert Blum, Managing Partner